

Transdermal Drug Delivery

Technologies, Companies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

Novemer 2017

A Jain PharmaBiotech Report

A B O U T T H E A U T H O R

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (1st ed 2008, 2nd ed 2014) and Drug Delivery to the Central Nervous System (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese ed, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Application of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Application of Biotechnology in Neurology" (Springer 2013), and "Application of Biotechnology in Oncology" (Springer 2014)

A B O U T T H I S R E P O R T

The original report on Transdermal Drug Delivery appeared as a section in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery as separate reports in 2000. In 2002, Transdermal Drug Delivery was also detached, expanded and updated to be issued as separate publications by Jain PharmaBiotech. The report was regularly updated since 2002, enlarged and rewritten for 2017 edition.

November 2017
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	10
1. Basics of Transdermal Drug Delivery	12
Introduction	12
Historical landmarks in transdermal drug delivery	12
Anatomy and physiology of skin	13
Skin metabolomics and transcutaneous passage of drugs	13
Transcutaneous absorption	14
Transdermal versus other methods of drug delivery	14
Advantages of transdermal drug delivery	14
<i>First-Pass Effect</i>	14
Drawbacks of transdermal delivery	14
Factors that influence transdermal drug delivery	15
Rate of permeation across the skin	15
Properties of the skin	16
Properties of drugs	16
<i>The role of pH and pharmacokinetics</i>	17
<i>Intradermal disposition of drugs after topical application</i>	17
Role of nanobiotechnology in understanding basis of transdermal delivery	17
2. Transdermal Drug Delivery Technologies	20
Introduction	20
Local application formulations	21
Crystalline topical formulations	21
Microemulsions for transdermal drug delivery	21
Nanoemulsions for transdermal drug delivery	22
Transdermal gel technology	22
Biphase system	24
Penetration enhancers	24
Chemical enhancers	24
<i>Nitric oxide-based transdermal drug delivery</i>	26
Ionic liquids for transdermal delivery of drugs against bacterial biofilms on skin	27
Vesicular transdermal carriers	27
<i>Liposomes</i>	27
<i>Transfersomes</i>	28
<i>Ethosomes</i>	28
<i>Elastic vesicles for transdermal drug delivery</i>	29
<i>Nanovesicles for transdermal drug delivery</i>	29
Transdermal patches	30
Adhesives for transdermal patches	31
Commercial development of transdermal patches	32
Innovations in transdermal patches	32
<i>e-Patch™ controlled release micropump system</i>	33
<i>Patchless Transdermal Delivery System</i>	33
<i>Metered-dose transdermal system</i>	34
Polymers for transdermal drug delivery	34
Polymer membranes in transdermal patches	35
Film forming polymeric solutions	36
Use of physical modalities to facilitate transdermal transport	36
Transdermal electrotransport	36
Electroporation	37
<i>Drug delivery by electroporation</i>	38
Cryoelectrophoresis	39
Iontophoresis	39
<i>Iontophoresis compared with electrophoresis</i>	40
<i>Application of iontophoresis for drug delivery</i>	40
<i>Patents in iontophoresis</i>	41
<i>Companies with technologies for drug delivery by iontophoresis</i>	42
Combination of electrophoresis and iontophoresis	42
<i>Dermaporation</i>	43
Radiofrequency-driven transdermal delivery	43
Microporation	43
Transcutaneous drug delivery by electropulsation	44
Companies involved in electroporation-based drug delivery	44
Electrode Scanning System	45
Use of electrostatic force in skin patch technology	45
Multiple Absorption Kinetic System	45

Transdermal drug delivery facilitated by heat	46
<i>Controlled, heat-aided drug delivery</i>	46
Ultrasound	46
Magnetophoresis.....	48
Use of lasers for transdermal drug delivery	48
<i>Laser-induced microporation</i>	48
<i>Transdermal drug delivery by laser-induced pressure waves</i>	49
<i>Transdermal drug delivery by laser-assisted changes in skin</i>	49
Transdermal delivery by gas under pressure	50
<i>Transdermal delivery with PowderJect gas gun</i>	50
<i>Microscission induced by gas</i>	51
Role of microelectronics in transdermal drug delivery	51
Microneedles and dermal microinjection technologies.....	51
Applications of microneedles	52
AdminPatch® microneedle array.....	53
Biodegradable microneedles.....	54
Ceramic microneedle arrays	54
Dissolvable microneedle patches.....	55
MicorCor.....	55
Microneedle arrays for drug delivery.....	55
Microneedle patch	56
MicroPyramid™ microneedles	57
Microstructured Transdermal Systems	57
Microneedle Array Patch technology	58
Microneedle transdermal chip.....	58
Microneedle applicator device.....	59
Nanoject™ microneedle technology	59
PatchPump.....	59
Polymer microneedles	60
Silk microneedles.....	60
Tattooing for drug delivery.....	61
ZP Patch microprojections technology.....	61
Companies developing microneedles for transdermal drug delivery	61
Needlefree injections.....	62
Glide SDI® solid dose injector.....	62
Jet injection	63
Mini-Ject needlefree delivery system	63
MicroJet for painless injections	63
Nanoliter-volume pulsed microjets	64
SUMAVEL™ DosePro™ needle-less injection	64
Skin ablation or abrasion for drug delivery	64
Nanotechnology-based transdermal drug delivery.....	65
Delivery of nanostructured drugs from transdermal patches	65
Effect of mechanical flexion on penetration of bucky balls through the skin	65
Nanobiotechnology for transdermal application.....	65
<i>Nanoparticles and nanoemulsions for skin disorders</i>	65
<i>Nanopatches</i>	66
<i>Inocyte™ epidermal drug delivery system</i>	66
<i>Ionic nanoparticle technology</i>	67
<i>SLN gel for treatment of skin disorders</i>	67
<i>Topical delivery of siRNA- nanoparticle conjugates</i>	67
<i>Transdermal nanoparticle preparations for systemic effect</i>	68
<i>Transferosomes for transdermal drug delivery</i>	69
<i>Transdermal administration of nanocarriers</i>	69
Nanotechnology-based transdermal vaccination and immunotherapy.....	69
Safety issues of applications of nanomaterial carriers on the skin.....	70
Comparison of transdermal drug delivery systems	70
Transdermal drug design	70
In vitro testing of transdermal drug delivery systems	71
<i>Commercially available skin models for transdermal drug testing</i>	71
<i>FDA guidelines for post-approval changes in semisolid topical drugs</i>	72
In vivo testing of drug delivery systems	72
Infrared spectroscopy for evaluation of transdermal drug delivery.....	72
Modeling of transport through the skin.....	73
Concluding remarks on transdermal drug delivery technologies.....	73
Future developments in transdermal drug delivery	74
3. Transdermal Therapeutics	76
Introduction	76
Drugs that can be administered transdermally	76
Approved transdermal products	76

Drugs in clinical trials	78
Skin disorders.....	79
Cutaneous leishmaniasis	79
Hair loss	79
Iontophoretic drug delivery for nail disorders.....	80
Psoriasis	80
<i>Nanoemulsions for paclitaxel delivery in psoriasis.....</i>	<i>80</i>
<i>Iontophoresis for treatment of psoriasis.....</i>	<i>80</i>
Cardiovascular disorders	81
Transdermal estrogen for prevention of atherosclerotic cardiovascular disease	81
Transdermal drug delivery for angina pectoris	81
Transdermal drug delivery for hypertension	82
<i>Transdermal clonidine</i>	<i>83</i>
<i>Transdermal delivery of β-blockers for hypertension.....</i>	<i>83</i>
<i>Transdermal delivery of calcium channel blockers for hypertension</i>	<i>84</i>
Transdermal drug delivery for congestive heart failure.....	84
Transdermal beta blockers	84
Transdermal anticoagulants	85
Respiratory diseases.....	85
Asthma.....	85
Chronic obstructive pulmonary disease	86
Neurological and psychiatric disorders	87
Parkinson's disease	87
<i>Transdermal drug delivery for Parkinson's disease</i>	<i>87</i>
<i>Transdermal levodopa delivery systems.....</i>	<i>87</i>
<i>Transdermal dopamine agonists for Parkinson's disease.....</i>	<i>88</i>
<i>Rotigotine for Parkinson disease</i>	<i>89</i>
<i>Rotigotine for restless legs syndrome</i>	<i>91</i>
<i>Transdermal administration of other drugs for Parkinson disease</i>	<i>91</i>
Depression.....	91
<i>Antidepressants.....</i>	<i>92</i>
<i>Selective serotonin-reuptake inhibitors</i>	<i>92</i>
<i>Transdermal fluoxetine</i>	<i>92</i>
<i>Monoamine oxidase inhibitors.....</i>	<i>93</i>
<i>Transdermal selegiline.....</i>	<i>93</i>
<i>Trazodone hydrochloride.....</i>	<i>94</i>
<i>Venlafaxine</i>	<i>94</i>
<i>Bupropion</i>	<i>94</i>
Bipolar disorder	95
<i>Transdermal lithium</i>	<i>95</i>
Schizophrenia.....	96
<i>Transdermal haloperidol</i>	<i>96</i>
<i>Transdermal risperidone for treatment of schizophrenia.....</i>	<i>96</i>
<i>Transdermal blonanserin for treatment of schizophrenia</i>	<i>96</i>
Restless legs syndrome	97
Alzheimer's disease.....	97
<i>Transdermal rivastigmine.....</i>	<i>97</i>
<i>Transdermal donepezil.....</i>	<i>98</i>
<i>Transdermal galantamine.....</i>	<i>98</i>
<i>Transdermal arecoline</i>	<i>99</i>
Transdermal nicotine for Tourette syndrome	99
Attention deficit hyperactivity disorder.....	99
<i>Transdermal methylphenidate</i>	<i>99</i>
Migraine	100
<i>Transdermal sumatriptan</i>	<i>100</i>
<i>Transdermal zolmitriptan</i>	<i>101</i>
Epilepsy.....	101
Tinnitus/Vertigo.....	102
Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage.....	102
Musculoskeletal disorders.....	102
Osteoporosis	102
<i>Transdermal alendronate</i>	<i>102</i>
<i>Transdermal estrogen.....</i>	<i>103</i>
<i>Transdermal human parathyroid hormone.....</i>	<i>103</i>
Osteoarthritis	103
Transdermal therapy of diabetes	104
Insulin delivery in diabetes by transdermal patches.....	104
Microneedle patch for glucose-responsive insulin delivery	104
Patch monitoring system for insulin delivery	105
Sonic Applicator & Control Device for TDD of insulin	106
V-Go® disposable insulin delivery device	106

ViaDor System for TDD of insulin	106
Companies developing devices for transdermal insulin delivery	107
Transdermal therapy of oral antidiabetic agents.....	107
<i>Transdermal antidiabetic agents other than insulin</i>	108
Male disorders	108
Erectile dysfunction	108
<i>Topical and transdermal preparation for erectile dysfunction</i>	108
Hypogonadism in the male.....	109
<i>Topical testosterone</i>	109
Benign prostatic hypertrophy.....	111
<i>Tamsulosin TDS</i>	111
Women's health	111
Female sexual arousal disorder.....	111
Menopause.....	112
<i>Hormone replacement therapy for menopause</i>	112
<i>Effect of transdermal estradiol on bone density</i>	114
<i>Transdermal PTH for postmenopausal osteoporosis</i>	114
<i>Transdermal testosterone for low libido in postmenopausal women</i>	114
Breast disorders	115
Dysmenorrhea.....	115
Female infertility	115
Contraception	116
Female contraception	116
<i>Ortho Evra™</i>	116
<i>AG200-15</i>	117
<i>BAY86-5016</i>	117
<i>Desogestrel</i>	117
Male contraception	118
<i>Transdermal progestin plus testosterone</i>	118
Cancer	118
Delivery of the photosensitizer drug δ -amino levulinic acid.....	118
Intradermal delivery of cancer vaccines by adenoviral vectors	119
Nanoemulsion-based delivery of caffeine for skin cancer	119
Topical interferon α 2b for cervical cancer and precancerous lesions	119
Transcutaneous electroporation for delivery of anticancer drugs	120
Transdermal delivery of peptide cancer vaccines	120
Transdermal drug delivery for prostate cancer.....	120
<i>Transdermal nitroglycerine for prostate cancer</i>	120
<i>Transdermal estradiol gel for prostate cancer</i>	121
<i>Transdermal leuprolide acetate for prostate cancer</i>	121
Transdermal drug delivery for breast cancer.....	121
<i>Afimoxifene topical gel for breast cancer</i>	121
Pain	121
Relief of pain associated with minor medical procedures	121
Transdermal Lidocaine for relief of pain	122
<i>Transdermal Lidoderm® for postherpetic neuralgia</i>	122
Transdermal capsaicin for relief of pain	122
Nonsteroidal antiinflammatory drugs	122
<i>Topical NSAIDs</i>	123
<i>Transdermal ketoprofen</i>	124
<i>Topical opioids</i>	125
Cancer pain.....	125
<i>Transdermal fentanyl</i>	125
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	126
<i>Transdermal buprenorphine</i>	126
Chronic pain of non-malignant origin	127
Transdermal local anesthetics.....	127
Postoperative pain	127
<i>Transdermal fentanyl for the management of postoperative pain</i>	127
<i>Fibromyalgia</i>	128
Nanotechnology-based approved transdermal analgesic preparations	128
Nausea and vomiting	128
Motion sickness	128
Postoperative vomiting	128
Chemotherapy-induced nausea and vomiting	128
Antiaging strategies	129
Smoking cessation	129
Transdermal nicotine replacement.....	129
Use of nicotine patch for smoking cessation in pregnancy	130
Other methods of nicotine replacement	131
Other treatments for smoking cessation.....	131

Miscellaneous uses of transdermal drug delivery.....	131
Chronic fatigue syndrome	131
Overactive bladder and urinary incontinence	131
<i>Transdermal oxybutynin</i>	<i>132</i>
Viral infections.....	132
<i>Transdermal nanoparticles for immune enhancement in HIV.....</i>	<i>133</i>
<i>Transdermal IQP-0410 for HIV/AIDS</i>	<i>133</i>
Wound healing and ulcers	134
Transdermal gene therapy	134
Transdermal delivery of plasmid DNA by electroporation	134
Transdermal antisense therapy	135
Transdermal vaccination.....	135
The skin as an immune organ.....	136
Technologies for transdermal vaccination.....	136
<i>Dissolvable microneedle array for vaccine delivery</i>	<i>136</i>
<i>Electroporation for administering DNA vaccines</i>	<i>136</i>
<i>Microneedles for transdermal delivery of vaccines</i>	<i>137</i>
<i>Needle-free delivery of vaccines.....</i>	<i>138</i>
<i>Transcutaneous immunotherapy using nanodispersions</i>	<i>139</i>
Applications of transdermal vaccination	140
<i>HIV/AIDS vaccination by topical application.....</i>	<i>140</i>
<i>Transdermal DNA influenza vaccine.....</i>	<i>141</i>
<i>Transdermal Aβ vaccination for Alzheimer's disease</i>	<i>141</i>
<i>Transdermal vaccination for traveller's diarrhoea</i>	<i>141</i>
Transdermal nutraceuticals	142
Complications of transdermal therapy	142
Adverse effects of drugs	142
Overdose effect	143
Skin complications	143
<i>MRI-induced skin burns from transdermal patches</i>	<i>143</i>
4. Markets for Transdermal Drug Delivery	146
Introduction	146
Global markets for drug delivery	146
Geographical distribution of transdermal drug delivery markets	147
Emerging transdermal drug delivery markets in Asia	147
Transdermal technology markets in therapeutic areas	147
Angina pectoris.....	148
Attention deficit hyperactivity disorder.....	148
Erectile dysfunction	149
Hypertension.....	149
Osteoporosis	149
Pain therapeutics	149
Parkinson's disease	149
Smoking cessation	150
Transdermal hormone replacement therapy for menopause	150
Transdermal testosterone replacement therapy for hypogonadism in the male	150
Transdermal contraceptive market	150
Markets according to transdermal technologies.....	151
Markets for microneedle-based transdermal drug delivery.....	151
Marketing strategies for transdermal drug delivery.....	151
Marketing advantages of transdermal drug delivery.....	152
Unmet needs in transdermal drug delivery	152
Regulatory aspects that affect transdermal drug delivery markets.....	153
Future prospects of transdermal drug delivery	154
Growth of new technologies used in transdermal drug delivery	154
Prospects of transdermal delivery for drugs coming off patents.....	154
Transdermal delivery of biologicals.....	155
Transdermal delivery of cosmetics	155
5. Companies involved in transdermal drug delivery	156
Profiles of companies.....	156
Top companies in transdermal drug delivery.....	156
Collaborations.....	283
6. References.....	288

Tables

Table 1-1: Historical landmarks in the development of transdermal drug delivery	12
Table 1-2: Transdermal vs oral and intravenous drug delivery	14
Table 1-3: Size ranges of molecules that can be delivered by transdermal route.....	17
Table 2-1: Technologies for transdermal drug delivery	20
Table 2-2: Chemical enhancers of skin penetration	25
Table 2-3: Drug-in-adhesive versus reservoir type of transdermal patch.....	30
Table 2-4: Companies with transdermal patches for drug delivery.....	32
Table 2-5: Companies with technologies for drug delivery by iontophoresis.....	42
Table 2-6: Companies involved in electroporation-based drug delivery	45
Table 2-7: Companies developing microneedles for transdermal drug delivery.....	62
Table 2-8: Comparison of transdermal drug delivery systems.....	70
Table 3-1: Approved transdermal products	76
Table 3-2: Transdermal drugs in clinical trials or approval process.....	78
Table 3-3: Companies developing devices for transdermal insulin delivery	107
Table 3-4: Selected transdermal systems GLP-1 antidiabetic agents.....	108
Table 4-1: Worldwide drug delivery market growth 2016 to 2026	146
Table 4-2: Transdermal drug delivery markets for geographical regions 2016 to 2026.....	147
Table 4-3: Markets for transdermal products for therapeutic areas 2016-2026	148
Table 4-4: Markets according to transdermal technologies 2016-2026.....	151
Table 4-5: Marketing strategies based on transdermal drug delivery technologies.....	151
Table 5-1: Top ten companies in transdermal drug delivery	156
Table 5-2: Collaborations in transdermal drug delivery	283

Figures

Figure 1-1: Basic structure of the skin.....	13
Figure 1-2: Events governing transcutaneous drug absorption	15
Figure 2-1: Basic structure and function of transdermal drug delivery systems.....	30
Figure 2-2: Transdermal system for delivery of liquid drugs	31
Figure 2-3: A schematic view of electroporation.....	37
Figure 2-4: Depiction of breakdown of the stratum corneum during electroporation	38
Figure 2-5: A schematic drawing of Iontophoresis.....	39
Figure 2-6: SonoPrep ultrasonic skin permeation	47
Figure 2-7: A a schematic sketch of PowderJect gas gun.....	50
Figure 2-8: Drug delivery using different types of microneedles (MN).....	52
Figure 2-9: A schematic drawing of the microneedle patch.....	57
Figure 2-10: Preparation of solid-in-oil nanodispersion for transdermal application.....	66
Figure 3-1: Oral versus transdermal administration of a drug in Parkinson's disease	90
Figure 3-2: Control functions and user interface of insulin patch monitoring system.....	106
Figure 3-3: Transcutaneous immunotherapy using nanodispersions	140
Figure 4-1: Unmet needs in transdermal drug delivery	153